Personal information

Countries

Türkiye

Activities

Collapse all

Employment (2)

Kutahya Saglik Bilimleri Universitesi: Kütahya, TR

2019-09-15 to present | Phd. Student (Department of Medical Sciences)
Employment
Source: Self-asserted source
Semih ŞEKER

Emniyet Genel Müdürlüğü: Ankara, TR

2011-03-17 to present | Asistan (Kriminal Polis Laboratuvarı)
Employment
Source: Self-asserted source
Semih ŞEKER

Education and qualifications (3)

Kütahya Sağlık Bilimleri Üniversitesi: Kutahya, Kütahya, TR

2021-09-15 to present | Phd. (Faculty of Medicine Department of Medical Sciences)
Education
Source: Self-asserted source
Semih ŞEKER

Kütahya Dumlupınar Üniversitesi: Kutahya, Kütahya, TR

2007-09-15 to 2010-03-08 | Yüksek Lisans (Fen Bilimleri Enstitüsü)
Education
Source: Self-asserted source
Semih ŞEKER

Dumlupınar Üniversitesi: Kutahya, Kutahya, TR

2003-10-15 to 2007-06-15 (biololgy)
Education
Source: Self-asserted source
Semih ŞEKER

Works (5)

Comparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools

Journal of Cellular and Molecular Medicine
2025-01 | Journal article
DOI: 10.1111/jcmm.70254
Contributors: Semih Seker; Betul Sahin; Azmi Yerlikaya
Source: check_circle
Crossref

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa

Medical Oncology
2023-09-14 | Journal article
DOI: 10.1007/s12032-023-02173-9
Part of ISSN: 1559-131X
Contributors: Sezgin Zeren; Semih Seker; Gizem Akkaş Akgün; Emrah Okur; Azmi Yerlikaya
Source: Self-asserted source
Semih ŞEKER

The Senescence Program is Reduced in Proteasome Inhibitor Bortezomib-Resistant PC3 Prostate Cancer Cell Line

European Journal of Biology
2023-05-31 | Journal article
DOI: 10.26650/eurjbiol.2023.11240253
Part of ISSN: 2602-2575
Contributors: Ertan Kanbur; Semih Şeker; Ferah Budak; Azmi Yerlikaya
Source: Self-asserted source
Semih ŞEKER
grade
Preferred source (of 2)‎

Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.

Molecular medicine reports
2010-03-01 | Journal article
DOI: 10.3892/mmr_00000262
PMID: 21472244
Source: Self-asserted source
Semih ŞEKER

PROTEOZOM İNHİBİTÖRÜ MG132’NİN 4T1 MEME VE B16F10 MELANOMA KANSER HÜCRELERİNDEKİ SİTOTOKSİK ETKİLERİ

Journal of Science and Technology of Dumlupınar University
2009-08-15 | Journal article
Contributors: Semih ŞEKER
Source: Self-asserted source
Semih ŞEKER
How many people are using ORCID?